A Post-marketing Surveillance Study Evaluating the Safety and Tolerability of the Labeled Use of Hetero-Darbepoetin Alfa in Indian Patients

Trial Profile

A Post-marketing Surveillance Study Evaluating the Safety and Tolerability of the Labeled Use of Hetero-Darbepoetin Alfa in Indian Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors Hetero Drugs
  • Most Recent Events

    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top